Company Tagline
Decoding cellular messengers to enable curative treatments for cancer
Industry Category
Business Keywords
Company Description
Mursla Bio is a pioneering biotechnology research company dedicated to decoding cellular messengers, enabling the development of curative treatments, particularly in the field of oncology. Based in Cambridge, England, Mursla Bio is at the forefront of liquid biopsy technology, offering innovative solutions for early cancer detection and intervention.
Mursla Bio's groundbreaking In Vitro Diagnostic (IVD) blood test employs AI-empowered analysis of the multi-omics content of liver-derived extracellular vesicles, providing a non-invasive alternative to traditional liver biopsies. This approach allows for real-time monitoring and assessment, promising to transform cancer surveillance and treatment strategies.
With a focus on liver cancer, Mursla Bio's flagship test is poised to replace ultrasound for the surveillance of millions of high-risk patients. Located at 181 Cambridge Science Park, Cambridge, England CB4 0GJ, GB, Mursla Bio is committed to advancing the future of cancer diagnostics and therapeutics. We invite the manager of Mursla Bio to create a customized and exclusive company showcase and product listing on our platform.
Mursla Bio est une entreprise pionnière de recherche en biotechnologie dédiée au décodage des messagers cellulaires, permettant le développement de traitements curatifs, en particulier dans le domaine de l'oncologie. Basée à Cambridge, en Angleterre, Mursla Bio est à l'avant-garde de la technologie de biopsie liquide, offrant des solutions innovantes pour la détection précoce et l'intervention contre le cancer.
Le test sanguin de diagnostic in vitro (DIV) révolutionnaire de Mursla Bio utilise l'analyse assistée par l'IA du contenu multi-omique des vésicules extracellulaires dérivées du foie, offrant une alternative non invasive aux biopsies hépatiques traditionnelles. Cette approche permet une surveillance et une évaluation en temps réel, promettant de transformer les stratégies de surveillance et de traitement du cancer.
En mettant l'accent sur le cancer du foie, le test phare de Mursla Bio est sur le point de remplacer l'échographie pour la surveillance de millions de patients à haut risque. Située au 181 Cambridge Science Park, Cambridge, England CB4 0GJ, GB, Mursla Bio s'engage à faire progresser l'avenir du diagnostic et des traitements du cancer. Nous invitons le responsable de Mursla Bio à créer une vitrine d'entreprise et une liste de produits personnalisées et exclusives sur notre plateforme.
Key Personnel / Employees
Compare Companies Side by Side
Compare Mursla Bio with 3 companies in Biotechnology-Research
| Comparison Field |
Mursla BioMain Company |
Vyant BioView Profile |
ElyptaView Profile |
RecursionView Profile |
|---|---|---|---|---|
|
Founded Year
|
— | 0 | 2017 | 2013 |
|
Company Size
|
— | 51-200 | 11-50 | 501-1,000 |
|
City
|
Cambridge, England | Cherry Hill, NJ | Solna, Stockholm County | Salt Lake City, Utah |
|
Country
|
United Kingdom | United States | Sweden | United States |
|
Skills & Keywords
Comparing with main company
|
20 Total Skills
Biotechnology
Liquid Biopsy
Oncology
Cancer Diagnostics
Extracellular Vesicles
In Vitro Diagnostics
Liver Cancer
oncology
computational biology
biotech
cancer
diagnostics
techbio
biology
biomarker
liver
transcriptomics
liquid biopsy
extracellular vesicle
proteomics
|
16 Total
16 Unique
Unique Skills:
bioinformatics
clinical
cytogenetics
cytology
development
DNA probes
+10
|
5 Total
5 Unique
Unique Skills:
biomarkers
multi-cancer early detection
renal cell carcinoma
systems biology
urology
|
23 Total
23 Unique
Unique Skills:
artificial intelligence
data
disease
Diseases of Aging
Drug Discovery
Drug Repurposing
+17
|
4
Total Companies2013
Oldest Founded3
Countries64
Unique SkillsSimilar Companies
Other organizations in the same industry
GeneProof a.s.
Biotechnology-ResearchMolecular diagnostics for your routine. IVDR products available!
SOTIO Biotech
Biotechnology-ResearchShaping the future of cancer immunotherapies by translating compelling science into patient benefit.
Altin Biosciences
Biotechnology-ResearchAltin Biosciences develops first-in-class botanical drug candidates for global unmet medical needs
GENERI BIOTECH s.r.o.
Biotechnology-ResearchDNA-based products, oligonucleotides, CE IVD kits, GMP/GLP services
Alternative Company Names
This company is also known as